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Abstract 
We previously reported the presence of MUC2, MUC5AC and, for the first time, MUC5B 
in a 58-year-old male with pseudomyxoma peritonei (PMP). This is a report on the 
biochemical and immunohistochemical characterization of mucin in a 50-year-old 
female with the same rare illness. A right oophorectomy and appendicectomy and a 
resection of the involved omentum were performed. Approximately a litre of crude 
material in the sol and gel phases was obtained from the patient during laparotomy. 
This was briefly homogenized in 6 M guanidinium hydrochloride and proteolytic 
inhibitors and purified by density gradient centrifugation in caesium chloride. At 
laparotomy it was noted that the patient had appendiceal and ovarian masses as well 
as extensive mucinous deposits in the omentum and peritoneum. A mucinous 
adenocarcinoma of the appendix and ovary was confirmed on histology. The cells 
expressed both sulphated and non-sulphated acidic mucins. The presence of MUC2, 
MUC5AC, MUC5B and α-1-acid glycoprotein was shown by Western blotting and MUC4 
by immunohistochemical staining. MUC1 and MUC6 were not detectable in the tissue. 
The study confirms that MUC2, MUC5AC and MUC5B are produced in the mucus of 
patients with PMP. The expression of MUC4 in this disease has not been previously 
reported.  
Case Rep Gastroenterol 2011;5:5–16 
DOI: 10.1159/000323137 
Published online: 
January 7, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
6
Introduction 
Mucins are high-molecular-weight, heavily O-glycosylated glycoproteins that either 
form crude visco-elastic gels on the epithelial surfaces of the internal tracts of the body 
[1], or like MUC7 (a salivary mucin) are of the secreted and non-gel-forming kind [2]. 
Furthermore a host of transmembrane mucins, for example MUC1 and MUC4, have 
been described [3], and some of these have been found to function as tumour cell 
modulators affecting tumour cell phenotype, making them potentially useful clinically 
[4]. Overexpression and underglycosylation of mucins are found in certain cancers, for 
example MUC1, which is found to be elevated in carcinoma of the breast and associated 
with a poor prognosis [5]. 
Mucin genes are highly polymorphic due to the presence of long stretches of a variable 
number of tandem repeats that are heavily glycosylated. Mucin gene expression is 
relatively organ-specific and an extensive loss of normal mucin gene regulation may occur 
with intestinal metaplasia [6, 7] or malignancy [7, 8]. There has been an increasing 
interest in mucins in the diagnosis and immunotherapeutic treatment of carcinomas in 
general [9, 10]. 
It has previously been reported that pseudomyxoma peritonei (PMP), which was first 
described in 1842, is a disease of MUC2-expressing goblet cells, although the copious 
intraperitoneal mucinous ascites containing huge globules of extracellular mucin [11, 12] 
may also contain MUC5AC [13]. The accumulation of large amounts of extracellular 
mucus in the abdominal cavity is probably the main cause of the disease’s morbidity and 
mortality, irrespective of the site of origin [12]. The first and only report, to our 
knowledge, of the presence of MUC5B in tissue and gelatinous material of a 58-year-old 
male diagnosed with PMP was from our laboratory [13]. The expression of MUC2 in 
PMP accounts for both the voluminous deposits of extracellular mucus and in women 
would help distinguish the appendix rather than the ovary as the site of origin of the 
disease [14]. 
Our laboratory previously reported the presence of MUC2, MUC5AC and, for the 
first time, MUC5B in the crude mucus in the peritoneal cavity of a 58-year-old male 
with PMP [13]. Herein we report the biochemical and immunohistochemical 
characteristics of mucus obtained from a 50-year-old female with PMP following 
mucinous adenocarcinoma of the appendix and ovary. Again, we have shown the 
presence of MUC2, MUC5AC and MUC5B in the soluble phase of the viscous material 
in the abdominal cavity of the patient. More interestingly the immunohistochemistry of 
tissue, besides showing a positive expression for MUC2, MUC5AC and MUC5B, also 
showed the presence of MUC4, a transmembrane mucin, which to our knowledge has 
not been reported previously. 
Patient and Methods 
Case Report 
A 50-year-old woman presented with a six-month history of lower abdominal pain, weight loss and 
nausea. On examination she was found to have a large lower abdominal mass arising from the pelvis. A 
CT scan of the abdomen and pelvis revealed a large, multiseptated mass originating in the pelvis, with 
solid and cystic components. An omental cake was noted. On this basis, a clinical diagnosis of mucinous  
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ovarian malignancy was made. She was taken to the operating theatre for a laparotomy, at which a 
large ovarian mass was noted as well as extensive mucinous deposits on the omentum and peritoneum 
and an appendix mass. A right oophorectomy and appendicectomy were performed, as well as resection 
of the involved omentum. Histology confirmed a mucinous adenocarcinoma of the appendix with 
involvement of the ovary. The appendicular tumour had ruptured, and the omental and peritoneal 
deposits were consistent with mucinous deposits from the ruptured appendix (PMP). 
Preparation and Analysis of Mucin 
One litre of viscous fluid from the patient’s abdomen, containing sol and gel phases, was provided on 
ice to the laboratory by the colorectal surgeons. Extraction of mucus and isolation of purified mucin 
were performed as described by Mall et al. [13]. Briefly, soluble mucus was treated with 10 mM 
dithiotreitol (DTT) in 6 M guanidinium hydrochloride (GuHCl), 5 mM EDTA, 0.1 M Tris-HCl buffer 
pH 8.0, for 5 h at 37.0°C or 0.2 M sodium dihydrogen phosphate buffer, pH 8.0, for reduction of mucins 
and subsequently alkylated with 25 mM iodoacetamide (IAA) for 15 h at room temperature in the dark 
[15–18]. Mucin subunits were separated by gel electrophoresis in 1% (w/v) agarose gels and Western 
blotting performed as described by Mall et al. [13], for MUC2, MUC5AC and MUC5B [19, 20]. An 
aliquot of mucin from the sol phase was subjected to a density gradient in 3.5 M caesium chloride 
(CsCl)/4 M GuHCl, twice for 48 h at 105,000 g with a starting density of 1.39–1.42 g/ml [15–18]. The 
mucin-rich fractions were pooled, dialyzed against three changes of distilled water and lyophilized. 
Polyacrylamide gel electrophoresis, Western blotting and amino acid analysis have also been described 
in detail by Mall et al. [13]. The polyclonal antibody for α-1-acid glycoprotein was raised in our 
laboratory and the second antibody was a goat anti-rabbit antibody (Dako, Cape Town). 
Analytical Determinations 
Glycoprotein was estimated using the periodic acid Schiff (PAS) procedure [21] and protein 
according to the method of Lowry et al. [22]. 
Histochemistry. Formalin-fixed paraffin wax-embedded (FFPE) tissue blocks were retrieved from the 
archives of the Division of Anatomical Pathology, National Health Laboratory Service (NHLS), Groote 
Schuur Hospital, Cape Town, South Africa. The FFPE blocks were cut and the 2 μm tissue sections were 
routinely stained for haematoxylin and eosin. Tissue sections were also stained with the PAS/AB (alcian 
blue) and HID (high iron diamine)/AB. 
Immunohistochemistry. Primary mouse monoclonal antibodies MUC1, MUC1core (MUC1c), 
MUC2, MUC5AC and MUC6 were obtained from NovoCastra Laboratories, Newcastle upon Tyne 
(UK) and MUC4 was kindly donated by S. Batra, University of Omaha, USA. MUC5B was a gift from 
Prof. Dallas Swallow, University College, London, UK. The Primary Armenian Hamster antibody 
MUC1 (CT2) was kindly donated by Dr. Sandra Gendler, Mayo Clinic, Scottsdale, Arizona, USA 
(table 1). Breast cancer tissue was used as a positive control for MUC1, MUC1 (CT2) and MUC1c, 
normal colon for MUC2, MUC4 and MUC5B, and normal stomach for MUC5AC and MUC6. The 
APES-coated slides were incubated overnight at 50°C to fix the tissue onto the slide. The tissue sections 
were dewaxed in xylene, rehydrated through graded alcohols to water and treated with 1% hydrogen 
peroxide/methanol to quench endogenous peroxidase activity. Antigen retrieval was achieved using 
0.01 M citrate buffer pH 6 in a pressure cooker at full pressure. After cooling in tap water, blocking was 
done with normal goat serum for non-specific binding. MUC5B required reduction with 10 mM DTT 
and alkylation with 25 mM IAA for 30 min each at room temperature prior to blocking. Primary 
antibody incubation times were as follows: 30 min for MUC1, MUC1 core and MUC5AC, 1 h for 
MUC2 and MUC5B, 2 h for MUC1 (CT2) and MUC6, all at room temperature. MUC4 was incubated 
overnight at 4°C. Phosphate-buffered saline Tween pH 7.4 was used for the washes. The specific 
secondary antibody (Envision Mouse from DakoCytomation for MUC1, MUC1c, MUC2, MUC4, 
MUC5AC, MUC5B and MUC6) or biotinylated goat anti-Armenian from SantaCruz for MUC1 
(CT2) was applied for 30 min at room temperature. The MUC1 (CT2) required another detection 
step using avidin/HRP (DakoCytomation). The substrate-chromogen DAB (3,3-diaminobenzidine 
tetrahydrochloride) was applied to develop the color intensity, enhanced with 1% copper sulphate, 
counterstained with haematoxylin, rehydrated through graded alcohols to xylene and coverslipped 
using entellan. The primary antibody was omitted in the negative control. Staining of the tissue was 
graded as follows: <5% = 0, 5–25% = 1, 26–50% = 2, 51–75% = 3, >75% = 4.  
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Ethics 
The University of Cape Town Research Ethics Committee approved the study (ethics number REC 
REF: 302/2005). 
Results 
Macroscopy 
One specimen consisted of a hyperaemic appendix measuring 75 × 25 × 18 mm, the 
distal segment of which showed marked globular enlargement with mural perforation. 
On cut section, it was noted that the appendiceal wall was thickened and the appendiceal 
lumen contained abundant glistening, highly viscous mucus which also clung to the 
serosal surface of the organ (fig. 1a). The right ovary consisted of a ruptured, 
multiloculated, cystic ovarian mass measuring 240 × 220 × 70 mm and containing 
massive quantities of highly viscous, yellowish, glistening mucus similar to that seen 
within the appendix. A 520-mm-long sheet of omentum contained multiple mucinous 
deposits (fig. 1b). 
Microscopy 
Sections of the appendix showed focal superficial papillary projections lined by atypical 
mucinous epithelium including numerous goblet cells. The tumour consisted of irregular 
mucinous glands and clusters of epithelial cells lying in large pools of extracellular mucus. 
There was invasion through the muscularis propria with abundant production of 
extracellular mucus which dissected through the wall. The wall of the appendix was 
perforated in areas, with spilling of mucus onto the serosal surface. The appendiceal 
resection margin was clear of invasive tumour and epithelial dysplasia. The ovary showed 
dissection of ovarian stroma by large pools of mucus with focal papillary architecture. The 
epithelium consisted of numerous goblet cells with basally oriented nuclei and apical 
mucin. Also noted were widespread stromal and surface peritoneal deposits of mucinous 
epithelium lying within large pools of mucin. Extensive omental deposits of tumour, 
essentially identical to that seen in the ovary and the appendix, were present. Based on the 
above findings a mucinous adenocarcinoma of the appendix with involvement of the 
right ovary and PMP was diagnosed. 
The histochemistry results (table 2) were similar for both the appendiceal and ovarian 
tumours. The tumour cells secreted predominantly acidic mucins (AB-positive) 
consisting of a mixture of sulphated and non-sulphated acidic mucin (HID/AB stain). 
More than 75% of tumour cells showed cytoplasmic staining for MUC2 (fig. 2a) and 
MUC5AC (fig. 2b). Between 50 and 75% of tumour cells expressed MUC4 (fig. 2c) in the 
cytoplasm. MUC5B (fig. 2d) expression was higher in the goblet cells of the appendix 
tumour than in the ovary. MUC1, MUC1 (CT2), MUC1c and MUC6 were negative. 
MUC2, MUC4, MUC5AC and MUC5B were co-expressed by neoplastic cells.  
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Purification of Mucins by CsCl Density Gradient Ultra-Centrifugation 
Mucins extracted from the viscous crude PMP material were purified by density 
gradient centrifugation, twice in CsCl and 4 M GuHCl with a buoyant density between 
1.39 and 1.40 g/ml to remove proteins and nucleic acids. After the second spin, there was 
a clear separation of the proteins from the mucins (fig. 3) [13]. The mucin-rich fractions 
were pooled, dialyzed against three changes of distilled water and lyophilized. 
SDS-PAGE and Western Blotting. Equal loadings of purified mucin samples on a 10% 
gel stained for mucin with PAS (fig. 4) showed PAS-positive material on the top of the 
stacking gel (fig. 4, lanes 1–6), with varying amounts of material in the stacking gel, 
moving into the running gel. There seemed to be no difference between untreated crude 
material (fig. 4, lane 1), that which was reduced with 10 mM DTT and alkylated with 
25 mM IAA (fig. 4, lane 2) and that which was digested with papain (fig. 4, lane 3), which 
showed material at the top of the stacking gel and the beginning of the running gel, just 
below molecular size 205 kDa. When crude material was digested and reduced, more 
material was released and appeared as a smear in the stacking gel and into the running gel 
(fig. 4, lane 4). Purified material (fig. 4, lane 5) released more PAS-positive material when 
reduced with 0.2 M 2-mercaptoethanol (fig. 4, lane 6), quite similar to crude material 
when reduced and digested (fig. 4, lane 4). A distinct smaller-sized species of mucin of 
higher electrophoretic mobility and varying intensity was seen at a molecular weight of 
approximately 40–50 kDa (fig. 4, lanes 1–6), which was more prominent in the purified 
samples (lanes 5 and 6) than in the crude samples. This 40–50 kDa glycoprotein was also 
seen in the serum of a patient with carcinoma of the stomach upon staining with PAS 
[23] and reacted strongly in a Western blot using the polyclonal antibody to α-1-acid 
glycoprotein for serum from the same patient (fig. 5, lane 3). An even stronger reaction 
was seen for the purified mucin for PMP (fig. 5, lane 2), which gave two very intense 
reactions. This mucin stains with PAS in SDS-PAGE (fig. 5, lane 5). 
Agarose Gel Electrophoresis and Western Blotting. Western blotting showed the 
presence of MUC5AC (fig. 6a, lane 2), MUC5B (fig. 6b, lanes 2–4) and MUC2 (fig. 6c, 
lanes 2 and 3). Each experiment had a positive and negative control, confirming the 
specificity of the antibody. 
Discussion 
It has been reported that PMP originates in the appendix rather than the ovary [24] 
and is associated with a high MUC2 expression which confirms the intestinal rather than 
an ovarian origin for the disease [12]. Whilst MUC2 appears to be a reliable molecular 
marker for PMP [12–14], the expression of MUC5AC, albeit in lesser amounts, has also 
been reported in this disease [13, 14]. MUC2 is the dominant mucin in the colon [25] and 
MUC5AC is found in the stomach [26] and respiratory tract [27]. 
In a previous study of a 58-year-old male patient [13] we showed the expression of not 
only MUC2 and MUC5AC, but also, for the first time, the presence of MUC5B [13], in 
the very viscous mucus in PMP [27]. These mucins together with another gastric mucin, 
MUC6 [28], are secreted gel-forming mucins, which could explain the highly viscous 
nature of the material obtained from such patients, the occurrence of which is associated 
with the morbidity and mortality of the disease [12]. Sheehan et al. [29] reported that  
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respiratory mucus of a patient who died in status asthmaticus presented with tenacious 
plugs of mucus [30] that ‘tether’ to the airway epithelium [31], presumably because of the 
presence of two glycoforms of MUC5B. The difficulties of the extraction of mucus from 
human small intestine which expresses largely MUC2, even in chaotropic agents such as 
guanidinium chloride, producing an insoluble glycoprotein complex, have been 
previously reported [25]. 
In this study we obtained mucus from a 50-year-old female with PMP that originated 
in the gastrointestinal tract and spread to the ovary. Biochemical analysis of the soluble 
phase of the visco-elastic material in the abdominal cavity of the patient again showed the 
presence of MUC2, MUC5AC and MUC5B (to our knowledge MUC5B has not been 
previously shown in this material in a female patient), and α-1-acid glycoprotein. This 
particular PAS-positive glycoprotein has previously been reported
 in crude mucus 
scrapings of patients with carcinoma of the stomach, which was later identified as 
α-1-acid glycoprotein, a marker for inflammation [23, 32, 33]. Interestingly α-1-acid 
glycoprotein was expressed in the parietal cells of the gastric mucosa rather than the 
mucin-producing cells [33]. We now report it to be present in purified material obtained 
from PMP. 
Immunohistochemical studies showed, in addition, the presence of MUC4, a 
transmembrane mucin, which again to our knowledge has not been previously reported. 
MUC4 has been reported to be a significant clinical marker in the diagnosis of pancreatic 
cancer [4, 34], an aggressive cancer that is increasing worldwide with a survival rate 
ranging from 4 to 6 months for patients diagnosed with metastatic disease [35]. MUC4 is 
not expressed in normal pancreas or chronic pancreatitis, but is highly expressed in 
human pancreatic carcinomas [36–38]. The expression of MUC4 in this case in both the 
primary appendiceal tumour and in the ovary, at a level >50%, warrants a closer 
investigation of the potential role of MUC4 in the diagnosis and prognosis of PMP. The 
limited range of antibodies in our possession allowed for the staining of only those 
mucins reported in this study. It is possible that the tissue and secreted material obtained 
from this patient expresse mucins besides those reported here. 
As in our previous study on the biochemistry of PMP, the high viscosity of the material 
obtained from such patients makes it extremely difficult to solubilize despite reduction 
with DTT during the extraction process, resulting in a low yield of soluble material 
available for further purification of mucins for analysis. Different methods of removing 
the protein which could be contributing to the viscosity of the material are being 
considered. Thus far we have found preparative gel filtration to be unsuccessful due to 
blockages in the Sepharose 2B column even after rather extensive dilution of the sample 
[13]. In this study analysis by SDS-PAGE showed that mucus had to be both reduced with 
DTT and digested with enzyme/papain prior to electrophoresis to enable the entry of 
mucin into the gel, albeit still at the top of the gel. This could well be through the presence 
of MUC5B [13], a lowly charged glycoform which is thought to be responsible for the 
tenacity of respiratory mucin secretions in asthma [29]. Also the huge amounts of protein 
associated with material in samples obtained from patients with PMP could contribute to 
the viscous nature of the material [13]. 
We have found gel-forming mucins MUC2, MUC5AC, MUC5B and a transmembrane 
mucin MUC4 in the abdominal fluid and neoplastic tissue of a patient with PMP. The 
appearance of MUC5B in this study and previously [13] and MUC4 in this case are, to  
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our knowledge, new findings which require further investigation with respect to the 
morbidity and mortality of the disease and the diagnostic and prognostic potential of 
these mucins in this disease. 
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Table 1. Antibodies used for immunohistochemistry in this study and their sources 
Antibody Clonality  mAbs  Clone  Dilution  Manufacturer 
MUC1 mouse  Ma695  1:100  NovoCastra 
MUC1  hamster  CT2  1:100  Mayo Clinic, USA 
MUC1c mouse  Ma552  1:100  NovoCastra 
MUC2 mouse  Cep58 1:100  NovoCastra 
MUC4  mouse  8G7  1:500  University of Omaha, USA 
MUC5AC mouse  CLH2  1:100  NovoCastra 
MUC5B mouse  5Bb2-2  1:100  E.U.  Consortium 
MUC6 mouse  CLH5 1:100  NovoCastra 
E.U. = European Union; mAb = monoclonal antibody. 
 
 
Table 2. Histochemical and immunohistochemical data 
H&E PAS/AB  HID  MUC1  MUC1c  MUC1 
(CT2) 
MUC2 MUC4 MUC5AC  MUC5Bb2-2  MUC6
Appendix  
Mucinous 
cystadeno-
carcinoma 
Goblet cells AB pos 
Secreted mucin  
pred AB 
Mixed AB &
HID 
neg neg  neg  4+   
cyto-
plasmic 
3+  
cyto-
plasmic 
4+  
cyto-
plasmic 
3+  
mainly 
goblet 
neg 
Ovary  
Metastatic 
mucinous 
cystadeno-
carcinoma 
Goblet cells AB pos 
Secreted mucin  
pred AB 
Mixed AB &
HID 
neg neg  neg  4+   
cyto-
plasmic 
3+  
cyto-
plasmic 
4+  
cyto-
plasmic 
2+ neg 
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Fig. 1. a Cut section of the appendix showing distal cystic enlargement with abundant thick mucus. 
b A multiloculated cystic ovarian mass with abundant viscous mucus. 
 
 
Fig. 2. Cytoplasmic staining for MUC2 (a), MUC5AC (b), MUC4 (c) and MUC5B (d). 
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Fig. 3. Second CsCl density gradient centrifugation of human mucus from a patient with PMP. Solid 
CsCl was added to semi-purified mucins obtained from the first CsCl density centrifugation spin to 
give a starting density of 1.39–1.40 g/ml. After centrifugation (40,000 r.p.m. for 48 h) the tubes were 
fractionated into 9 equal fractions and the density, mucin and protein of each fraction. 
 
 
 
Fig. 4. 10% SDS-PAGE, stained with PAS, of crude and purified mucin from a patient with PMP. 
Lane 1: crude material; lane 2: crude material reduced with DTT; lane 3: crude material digested with 
papain; lane 4: crude material digested and reduced; lane 5: purified mucin; lane 6: purified mucin 
reduced with DTT. 
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Fig. 5. A composite of a 10% SDS-PAGE gel stained with PAS (lanes 4 and 5) and a Western blot of 
material stained with the antibody against α-1-acid glycoprotein (lanes 2–3). Lane 1: molecular weight 
marker; lane 2: purified mucin from a patient (in this study) with PMP; lane 3: serum from a patient 
diagnosed with carcinoma of the stomach; lane 4: purified mucin from a patient (in this study) with 
PMP (PAS stain); lane 5: molecular weight marker. 
 
 
 
Fig. 6. Western blot following agarose gel electrophoresis identifying mucins in PMP. a MUC5AC 
expression. Lane 1: gastric cancer (positive control); lane 2: crude PMP material. b MUC5B expression. 
Lane 1: saliva (positive control); lane 2: crude PMP material; lane 3: crude reduced PMP material; 
lane 4: purified PMP. c MUC2 expression. Lane 1: normal colon (positive control); lane 2: purified 
PMP; lane 3: purified reduced PMP. 
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